stockrow
Friday 6 November 2026
Export INTS’s income statement to Excel — free account
Intensity Therapeutics Inc.
INTS Healthcare Biotechnology
- EPS
- +65.9%
- Free cash flow
- +4.72%
- Total debt
- −34.7%
Quarter to June 2026, against a year earlier
2.97
0.53
−15.14%
Follow INTS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 35 | 35 | 35 | 0.0% | |
| Gross margin, % | — | — | — | — | — | — | 0.00 | — | — | — | 0.00 | — | ||||||
| EBT | — | — | — | (5) | (6) | (8) | (8) | (11) | (16) | (12) | (11) | +13.7% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | (5) | (6) | (8) | (8) | (11) | (16) | (12) | (11) | +13.7% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.41) | (22.11) | (28.94) | (55.59) | (34.50) | (29.25) | (8.56) | (4.87) | +65.9% | ||||||
| Cash flow | — | — | — | (0.34) | (19.69) | (25.03) | (40.15) | (20.91) | (27.37) | (6.81) | (3.31) | +65.0% | ||||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (0.34) | (19.69) | (25.03) | (40.15) | (20.91) | (27.37) | (6.81) | (3.31) | +65.0% | ||||||
| Book value | — | — | — | 0.59 | 30.94 | 4.82 | (37.38) | 38.20 | 5.25 | 8.76 | 3.40 | +56.9% | ||||||
| Shares, m | — | — | — | 13 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | (31.5%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (4) | (5) | (7) | (5) | (7) | (15) | (9) | (9) | +13.1% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | (4) | (5) | (7) | (5) | (7) | (15) | (9) | (9) | +13.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 8 | 8 | 1 | (5) | 12 | 2 | 11 | 9 | +5.8% | |||||
| Net debt | — | — | — | (8) | (9) | (4) | (1) | (15) | (2) | (12) | (9) | +6.5% | ||||||
| Shareholders’ equity | — | — | — | 8 | 8 | 1 | (5) | 13 | 3 | 12 | 9 | +7.5% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (62.96) | (102.77) | (217.46) | (124.52) | (147.37) | (122.92) | (139.85) | (122.9) pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (2,366.58) | (22,007.35) | 0.00 | (22,007.3) pt | ||||||
| ROE | — | — | — | 0.00 | 312.47 | 154.16 | 63.76 | 1,225.41 | (202.34) | (156.90) | (195.88) | (156.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 16 | — | 7 | 7 | 7 | — | (18.7%) | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Intensity Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LPCN Lipocine Inc. | $12.6M | — (loss-making) | — (loss-making) | +1,898.32% (above 0%: growing) | n/m | +39.46% (above 0%: growing) | 100.00% | (37.93%) | Compare |
| TVRD Tvardi Therapeutics, Inc. | $11.5M | — (loss-making) | — (loss-making) | +20.33% (above 0%: growing) | n/m | −57.26% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| PBM Psyence Biomedical Ltd. | $11.2M | 0.1× | — | — | n/m | −707.20% (below 0%: shrinking) | — | 0.00% | Compare |
| PASG Passage Bio, Inc. | $11.1M | — (loss-making) | — | — | n/m | −59.81% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CLRB Cellectar Biosciences, Inc. | $10.9M | — (loss-making) | — | −73.23% (below 0%: shrinking) | n/m | −17.49% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LSTA Lisata Therapeutics, Inc. | $10.7M | — (loss-making) | — (loss-making) | −98.30% (below 0%: shrinking) | n/m | +33.04% (above 0%: growing) | 100.00% | 0.00% | Compare |
| BIVI BioVie Inc. | $10.3M | — (loss-making) | — | — | n/m | +26.50% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PTN Palatin Technologies, Inc. | $10.2M | 12.2× | 0.2× | −14.06% (below 0%: shrinking) | n/m | +34.21% (above 0%: growing) | 100.00% | (1,469.35%) | Compare |
| INTS Intensity Therapeutics Inc. | $10.1M | — (loss-making) | — | — | n/m | +4.72% (above 0%: growing) | 0.00% | 0.00% | |
| Median of peers | $11.0M | — | — | −14.06% | — | +4.51% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 30 April 2026
Ownership
Directors and executive officers, together
7.60%
Lewis H. Bender
6.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement